

Prognosis of patients with ABL-class positive B-ALL: need for an early identification and establishment of a controlled study aimed at investigating the benefits of addition of a TKI to chemotherapy

46 ABL-class fusion positive cases other than BCR-ABL1 treated (AIEOP-BFM ALL 2000 and 2009 protocols)



13

Tyrosine kinase inhibitor during treatment

Relapse

1/13



33

No Tyrosine kinase inhibitor during treatment

8/33

5-year probability of event-free survival	49.1±8.9%
5-year probability of overall survival	69.6±7.8%
Cumulative incidence of relapse	25.6±8.2%
Treatment-related mortality	20.8±6.8%

